INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a study of solanezumab initiated in people with mild dementia […]
Home / Posts Tagged "Eli Lilly and Company"
INDIANAPOLIS, Nov. 23, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer’s disease (AD). Patients treated with solanezumab did not experience a statistically significant slowing in […]
Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, […]
Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate – the current standard of care – and adalimumab (Humira®)* INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase […]
Lilly immunology portfolio to be featured in 16 presentations INDIANAPOLIS, June 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib’s phase 3 global studies will be presented, along with other phase 2b and preclinical studies, at […]
Trulicity 1.5 mg Demonstrates Superior Efficacy in AWARD-8 Trial INDIANAPOLIS, Dec. 1, 2015 /PRNewswire/ — New data from a completed Phase 3 trial show Trulicity® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering HbA1c from baseline after 24 weeks of treatment.1 Trulicity is Eli Lilly and […]
— Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab — Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab — Detailed results from pivotal phase 3 study RA-BEAM presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting INDIANAPOLIS, […]
– Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early as week 1 and maintained through 52 weeks – Both baricitinib regimens were superior to methotrexate monotherapy in inducing clinical remission, using measures such as SDAI, at weeks 24 and 52 – Baricitinib plus methotrexate […]